Alpha Tau Medical Ltd.
DRTSDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 10, 2026
5dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
DRTS Earnings Report
EPS Est: $-0.14 | FQ end 2026-06
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Alpha Tau Medical Ltd.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Alpha Tau Medical Ltd.'s (DRTS) pipeline across Phase 3, Phase 2. Its lead program is AZD3759 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Alpha Tau Medical Ltd.'s next FDA catalyst?→
Alpha Tau Medical Ltd.'s (DRTS) next tracked catalyst is a Earnings expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DRTS biotech catalysts?→
Add DRTS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alpha Tau Medical Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.